Search results
Showing 1351 to 1365 of 2008 results for nice guidelines
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.
What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?
review the evidence this. A cross-reference has been included to the NICE guideline on preventing sexually transmitted...
measurement of pulse, blood pressure and respiratory rate in line with the NICE guideline on sepsis . Hourly monitoring of...
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).
Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)
This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.